PURPOSE To evaluate bevacizumab toxicity in neurosensorial retina and retinal pigment epithelium in pigmented rabbit eyes by means of histological studies. METHODS Thirty eyes of fifteen rabbits were distributed into three groups: sham group (S), that received a 0.1 ml balanced saline solution (BSS) intravitreal injection (10 eyes); group 1, that received a 1.25 mg (0.1 ml) bevacizumab intrav...

Purpose. This study aims to evaluate the regression of retinopathy of prematurity (ROP) after one intravitreal injection of bevacizumab and the factors that influenced it. Methods. This retrospective case series was carried out at the "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania. It includes all the consecutive infants treated for ROP with one intravitreal bevaciz...

Dear Editor, Myopic choroidal neovascularisation (mCNV) is one of the most common causes of permanent central visual loss in patients with high myopia,1 and its natural history results in the development of chorioretinal atrophy around the regressed mCNV, causing further progressive central visual loss.2 Therefore there is a need to fi nd treatment options which will not only regress the mCNV b...

Purpose: To evaluate the safety and efficacy of intravitreal injection of bevacizumab advanced to vitrectomy for severe proliferative diabetic retinopathy. Methods: This is a prospective study in which, Ten eyes of ten patients with an average age 54.1 ±6.5 years (45-64 years old) complaining of severe proliferative diabetic retinopathy were investigated. An intravitreal injection of 1.25mg bev...

We report a case of bilateral Eales’ disease managed with intravitreal bevacizumab. A 32-year-old woman history bacillus Calmette-Guerin vaccine, administered when she was 10 years old, presented five-day scotoma in the temporal field her right eye. dilated fundus exam and fluorescein angiography showed retinal peripheral capillary non-perfusion, neovascularization eye, deep intraretinal hemorr...

PURPOSE To evaluate the therapeutic effect of intravitreal bevacizumab injection for symptomatic retinal arterial macroaneurysm. DESIGN Retrospective interventional case series. METHODS The study included 23 patients (23 eyes) with symptomatic retinal arterial macroaneurysm. They were categorized according to treatment method into 2 groups: an intravitreal bevacizumab-treated group (11 eyes...

PURPOSE To assess the effect of intravitreal bevacizumab for Type 1 retinopathy of prematurity (ROP) in zone II ROP. METHODS We conducted a randomized clinical trial. Preterm infants with a gestational age less than 34 weeks or birthweight less than 2000 g were examined at 4 weeks chronological age or 31 weeks postmenstrual age (whichever was later). Preterm infants with Zone-II/Stage 2 or 3 ...

IMPORTANCE Bevacizumab acquired from compounding pharmacies for intravitreal injection may cause infectious and noninfectious inflammation. In addition to safety issues, the drug itself may have variable efficacy associated with product aliquoting, handling, and distribution. OBJECTIVE To conduct surveillance cultures, evaluate endotoxin levels, and assess protein concentrations of bevacizuma...

This report describes a case of angiographically documented foveal avascular zone (FAZ) enlargement after a single intravitreal injection of bevacizumab for macular edema secondary to central retinal vein occlusion (CRVO). A 71-year-old female was treated with an intravitreal bevacizumab injection for macular edema following CRVO. Despite successfully decreased edema one month after injection, ...

We report a patient with progression to a macula-off tractional retinal detachment in a fellow eye after a contralateral intraoperative intravitreal bevacizumab injection. A 32-year-old diabetic man noted decreased vision in his left eye 1 week following 25 gauge pars plana vitrectomy, gas tamponade, and intraoperative injection of bevacizumab in his right eye. Left eye visual acuity decreased ...